

B2 5. The method of claim 1, wherein cross-priming of antigens is stimulated in said mammal.

B3 7. The method of any one of claims 1-5, wherein said lactadherin or fragment thereof is human lactadherin or a fragment thereof.

Please add the following claims

20. The method of claim 1, to produce cytotoxic T lymphocytes specific for a selected antigen.

21. The method of claim 1, wherein said lactadherin has the amino acid sequence of SEQ ID NO:2 or 4 or a fragment thereof comprising a functional integrin binding site.

22. The method of claim 1, wherein said lactadherin or fragment thereof is fused to an antigenic polypeptide or peptide.

23. The method of claim 1, comprising administering to said mammal a nucleic acid encoding said lactadherin or fragment thereof.

24. The method of claim 1 for stimulating a CTL response in a mammal towards an antigen, the method comprising administering to said mammal an antigenic polypeptide or peptide fused to said lactadherin or fragment thereof.

25. The method of claim 24, wherein the antigen is selected from viral proteins, bacterial proteins and tumor antigens.

26. The method of claim 24, wherein said lactadherin has the amino acid sequence of SEQ ID NO:2 or 4 or a fragment thereof comprising a functional integrin binding site.

27. A method for stimulating a CTL response in a mammal towards an antigen, the method comprising administering to said mammal a nucleic acid encoding an antigenic

polypeptide or peptide fused to said lactadherin or fragment thereof.

28. The method of claim 27, wherein the antigen is selected from viral proteins, bacterial proteins and tumor antigens.

29. The method of claim 27, wherein said lactadherin has the amino acid sequence of SEQ ID NO:2 or 4 or a fragment thereof comprising a functional integrin binding site.

---